ALIGOS THERAPEUTICS INC
ALGSNASDAQ🏆 #3464 by market capEarnings Nov 4US Equity
$7.31▼ $0.31 (−4.19%)
Market closed · at close1h—
24h▼ 4.2%
7d▲ 54.2%
14d▲ 71.2%
30d▲ 13.0%
1y▼ 2.5%
🏦Market Cap
$45M
Small Cap
📈Revenue Growth (YoY)
+43.9%
High Growth
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
10.2x
Elevated
Otter Score
46
Weak
Trading Snapshot
- Day Range
- $7.24 – $7.35
- 52-Week Range
- $3.98 – $13.69
- Volume
- $3.90B
- Avg Volume
- $4.94B
- Shares Outstanding
- 6.2M
- Next Earnings
- Oct 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 10.2x
- EPS (TTM)
- $-8.70
- Dividend Yield
- —
Why Investors Own ALGS
- ✓High-growth profile — revenue up +52.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$5M▲ +52.6% YoY
Gross Margin (TTM)
37.7%▲ +0.2% YoY
Operating Income (TTM)
$1M▲ +52.6% YoY
Free Cash Flow (TTM)
$1M▲ +52.6% YoY
About ALIGOS THERAPEUTICS INC
A company profile for ALIGOS THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$7.24
▼ −0.9% Downside
High Target$9.12
Low Target$5.72
Based on 35 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
ALIGOS THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift ALGS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
ALIGOS THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.